Azenam 250 Injection
Aztreonam
250mg
Aristo Pharmaceuticals Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Azenam 250 Injection is used for:
Bone and joint infections; Intra-abdominal infections; Lower respiratory tract infections; Meningitis; Septicaemia; Skin and soft tissue infections ; Pelvic infections, Gonorrhoea; Cystitis, Urinary tract infections, Cystic fibrosis
Adult Dose
Adult: IV/IM Gm-ve infections 1-8 g/day in divided doses depending on severity. Max: 8 g/day.
UTI 0.5-1 g 8-12 hrly.
IM Cystitis; Gonorrhoea 1 g as a single dose.
Child Dose
Child: IV, IM 90–120 mg/kg/day q6–8hr
Infants >1 wk: 30 mg/kg every 6 or 8 hr
Renal Dose
Renal impairment
CrCl 10-30 mL/min: 1-2 g loading dose, then 50% of usual dosage
CrCl <10 mL/min: 1-2 g loading dose, then 25% of usual dosage
Administration
Reconstitution:
IM: Reconstitute vial w/ at least 3 mL of sterile water for inj, sterile bacteriostatic water for inj, normal saline, or bacteriostatic NaCl per g of aztreonam; immediately shake vigorously.
IV: Bolus inj: Reconstitute vial w/ 6-10 mL of sterile water for inj.
Infusion: Reconstitute vial w/ at least 3 mL of sterile water for inj per g of aztreonam; immediately shake vigorously. Then further dilute in an appropriate soln for infusion to a final concentration of <2%.
Contra Indications
Hypersensitivity to aztreonam.
Precautions
History of β-lactam hypersensitivity. Renal and hepatic impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor for signs of anaphylaxis during 1st dose; periodic LFT. Consider measuring FEV1 prior to initiation of inhalation therapy.
Lactation: Drug is excreted in milk in low concentrations; use not recommended (American Academy of Pediatrics committee states that drug is compatible with nursing)
Pregnancy-Lactation
Interactions
Concurrent use w/ oral anticoagulants may increase prothrombin time.
Adverse Effects
Side effects of Aztreonam :
>10%
Injection
Pain at injection site (12%; children); (2%; adults)
Increase in serum transaminases (4-6%)
Neutropenia (3-11%, children); (<1%, adults)
1-10%
Rash (4%),Thrombocytopenia (4%, children); (<1% adults),Diarrhea (1%),Nausea (1%),Vomiting (1%),Fever (<1%)
< 1%
Abnormal taste,Anaphylaxis,Anemia,Angioedema,Aphthous ulcer,Breast tenderness,Bronchospasm,Clostridium difficile-associated diarrhea (CDAD),Confusion,Diplopia,Dizziness,Dsypnea,Electrocardiographic changes (transient),Erythema multiforme,Eosinophilia,Fever,Flushing,Halitosis,Headache,Hepatitis,Hypotension,Insomnia,Jaundice,Leukocytosis,Neutropenia,Pancytopenia,Seizures,Thrombocytopenia,Tinnitus,Tongue numbness,Toxic epidermal necrolysis,Urticaria,Vaginitis,Vertigo,Weakness,Wheezing
Potentially Fatal: Clostridium difficile-associated diarrhoea from mild diarrhoea to fatal colitis.
Mechanism of Action
Aztreonam inhibits bacterial cell wall synthesis due to its high affinity for penicillin-binding protein 3 (PBP-3) of gm-ve bacteria. It is highly resistant to hydrolysis by many narrow-spectrum β-lactamases. It is also active against most Enterobacteriaceae (including E. coli, Citrobacter, Enterobacter, Klebsiella, Proteus, Providencia, Salmonella, Serratia, Shigella, Yersinia spp. and Morganella morganii).
Note
Azenam 250 250mg Injection manufactured by Aristo Pharmaceuticals Ltd.. Its generic name is Aztreonam. Azenam 250 is availble in Nepal.
Farmaco Nepal drug index information on Azenam 250 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.